Edition:
United Kingdom

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

10.91USD
19 Apr 2018
Change (% chg)

$-0.10 (-0.91%)
Prev Close
$11.01
Open
$11.08
Day's High
$11.27
Day's Low
$10.89
Volume
49,769
Avg. Vol
70,258
52-wk High
$15.08
52-wk Low
$5.45

Chart for

About

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $404.27
Shares Outstanding(Mil.): 48.71
Dividend: --
Yield (%): --

Financials

  CCXI.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.62 -- --
ROI: -27.86 14.84 14.38
ROE: -59.68 16.34 16.07

BRIEF-Chemocentryx Q4 Revenue $56.3 Million Versus $4.9 Million

* CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

09 Mar 2018

BRIEF-Chemocentryx Secures Up To $100 Million In New Capital Commitments

* CHEMOCENTRYX SECURES UP TO $100 MILLION IN NEW CAPITAL COMMITMENTS

04 Jan 2018

BRIEF-ChemoCentryx Says EMA Accepts Vasculitis Drug Avacopan For Conditional Review

* AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-Chemocentryx reports Q3 revenue $9.0 million

* Chemocentryx reports third quarter 2017 financial results and recent highlights

07 Nov 2017

Competitors

Earnings vs. Estimates